PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Siderowf, Andrew ^a   Pontecorvo, Michael J ^a   Shill, Holly A ^b   Mintun, Mark A ^a   Arora, Anupa ^a   Joshi, Abhinay D ^a   Lu, Ming ^a   Adler, Charles H ^c   Galasko, Douglas ^d   Liebsack, Carolyn ^b   Skovronsky, Daniel M ^a   Sabbagh, Marwan N ^b  

^a AVID RADIOPHARMACEUTICALS   (United States)

^b SUN HEALTH RESEARCH INSTITUTE   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alzheimer's disease; Biomarkers; Parkinson's disease; PET imaging

Indexed keywords

AMYLOID; DOPAMINE; FLORBENAZINE F 18; FLORBETAPIR F 18; VESICULAR MONOAMINE TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2; BIOLOGICAL MARKER; FLUORINE 18; ANILINE DERIVATIVE; DRUG COMBINATION; ETHYLENE GLYCOL DERIVATIVE; FLORBETAPIR; FLUORINE; RADIOPHARMACEUTICAL AGENT; TETRABENAZINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DIAGNOSIS RELATED GROUP; DIFFUSE LEWY BODY DISEASE; FEMALE; HUMAN; MALE; MIDDLE AGED; NERVE DEGENERATION; NEUROIMAGING; PARKINSON DISEASE; PATHOPHYSIOLOGY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PROTEIN BINDING; PROTEIN FUNCTION; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DIAGNOSTIC TEST ACCURACY STUDY; MENTAL HEALTH; MINI MENTAL STATE EXAMINATION; MOTOR PERFORMANCE; OCCIPITAL CORTEX; PATIENT SAFETY; PROGNOSIS; SENSITIVITY AND SPECIFICITY; URINARY TRACT INFECTION; ADVERSE EFFECTS; AMYLOID PLAQUE; ANALOGS AND DERIVATIVES; DRUG COMBINATION; IMAGE PROCESSING; METABOLISM; PROCEDURES; SCINTISCANNING; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; ANILINE COMPOUNDS; DOPAMINE; DRUG COMBINATIONS; ETHYLENE GLYCOLS; FEMALE; FLUORINE RADIOISOTOPES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEWY BODY DISEASE; MALE; MIDDLE AGED; PLAQUE, AMYLOID; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; TETRABENAZINE;

EID: 84901228427     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-14-79     Document Type: Article

References (40)

1. Barker WW, Luis CA, Kashuba A, Luis M, Harwood DG, Lowenstein D, Waters C, Jimison P, Shepherd E, Sevush S, Graff-Radford N, Newland D, Todd M, Miller B, Gold M, Heilman K, Doty L, Goodman I, Robinson B, Pearl G, Dickson D, Duara R. Relative Frequencies of Alzheimer Disease, Lewy Body, Vascular and Frontotemporal Dementia, and Hippocampal Sclerosis in the State of Florida Brain Bank. Alzheimer Dis Assoc Disord 2002, 16:203-212. 10.1097/00002093-200210000-00001, 12468894.
2. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005, 65:1863-1872. 10.1212/01.wnl.0000187889.17253.b1, 16237129.
3. Lippa CF, Duda JE, Grossman M, Hurtig HI, Aaersland D, Boeve BF, Brooks DJ, Dickson DW, Dubois B, Emre M, Fahn S, Farmer JM, Galasko D, Galvin JE, Goetz CG, Growdon JH, Gwinn-Hardy KA, Hardy J, Heutink P, Iwatsubo T, Kosaka K, Lee VM, Leverenz JB, Masliah E, McKeith IG, Nussbaum RL, Olanow CW, Ravina BM, Singleton AB, Tanner CM, et al. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 2007, 68:812-819. 10.1212/01.wnl.0000256715.13907.d3, 17353469.
4. Tiraboschi P, Salmon DP, Hansen LA, Hofstetter RC, Thal LJ, Corey-Bloom J. What best differentiates Lewy body from Alzheimer's disease in early-stage dementia?. Brain 2006, 129:729-735. 10.1093/brain/awh725, 16401618.
5. Tsuang D, Simpson K, Larson EB, Peskind E, Kukull W, Bowen JB, McCormick W, Teri L, Montine T, Thompson ML, Leverenz JB. Predicting Lewy Body Pathology in a Community-Based Sample With Clinical Diagnosis of AlzheimerΓÇÖs Disease. J Geriatr Psychiatry Neurol 2006, 19:195-201. 10.1177/0891988706292755, 17085757.
6. Olichney JM, Galasko D, Salmon DP, Hoffstetter CR, Hansen LA, Katzman R, Thal LJ. Cognitive decline is faster in Lewy body variant than in Alzheimer's disease. Neurology 1998, 51:351-357. 10.1212/WNL.51.2.351, 9710002.
7. Del-Ser T, Munoz DG, Hachinski V. Temporal pattern of cognitive decline and incontinence is different in Alzheimer's disease and diffuse Lewy body disease. Neurology 1996, 46:682-686. 10.1212/WNL.46.3.682, 8618667.
8. Grundman M, Pontecorvo MJ, Salloway SP, Doraiswamy PM, Fleisher AS, Sadowsky, Nair AK, Siderowf A, Lu M, Arora AK, Agbulos A, Flitter ML, Krautkramer MH, Sarsour K, Skovronsky DM, Mintun MA,45-A17 Study Group Potential Impact of Amyloid Imaging on Diagnosis and Intended Management in Patients With Progressive Cognitive Decline. Alzheimer Dis Assoc Disord 2013, 27:4-15. 10.1097/WAD.0b013e318279d02a, 23203162, 45-A17 Study Group.
9. McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992, 305:673-678. 10.1136/bmj.305.6855.673, 1882909, 1356550.
10. Graff-Radford J, Boeve BF, Pedraza O, Ferman TJ, Przybelski S, Lesnick TG, Vemuri P, Senjem ML, Smith GE, Knopman DS, Lowe V, Jack CR, Petersen RC, Kantarci K. Imaging and acetylcholinesterase inhibitor response in dementia with Lewy bodies. Brain 2012, 135:2470-2477. 10.1093/brain/aws173, 3407425, 22810436.
11. Klunk WE, Engler H, Norberg A, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004, 55:306-309. 10.1002/ana.20009, 14991808.
12. Clark CM, Schneider JA, Bedell BJ, Beach TG, Bilker WB, Mintun MA, Pontecorvo MJ, Hefti F, Carpenter AP, Flitter ML, Krautkramer MJ, Kung HF, Coleman RE, Doraiswamy PM, Fleisher AS, Sabbagh MN, Sadowsky CH, Reiman EP, Zehntner SP, Skovronsky DM,AV45-A07 Study Group USe of florbetapir-pet for imaging beta-amyloid pathology. JAMA 2011, 305:275-283. 10.1001/jama.2010.2008, 21245183, AV45-A07 Study Group.
13. Brooks DJ. The early diagnosis of Parkinson's disease. Ann Neurol 1998, 44:S10-S18. 10.1002/ana.410440704, 9749569.
14. Okamura N, Villemagne VL, Drago J, Pejoska S, Dhamija RK, Mulligan RS, Ellis JR, Ackermann U, O'Keefe G, Jones G, Kung HF, Pontecorvo MJ, Skovronsky D, Rowe CC. In Vivo Measurement of Vesicular Monoamine Transporter Type 2 Density in Parkinson Disease with 18 F-AV-133. J Nucl Med 2010, 51:223-228. 10.2967/jnumed.109.070094, 20080893.
15. Villemagne VL, Okamura N, Pejoska S, Drago J, Mulligan RS, Chételat G, Ackermann U, O'Keefe G, Jones G, Gong S, Tochon-Danguy H, Kung HF, Masters CL, Skovronsky DM, Rowe CC. In vivo assessment of vesicular monoamine transporter type 2 in dementia with Lewy bodies and Alzheimer's disease. Arch Neurol 2011, 68:906-912.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDSΓÇÉADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939. 10.1212/WNL.34.7.939, 6610841.
17. Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of subjects for the clinician. J Psychiatr Res 1975, 12:189-198. 10.1016/0022-3956(75)90026-6, 1202204.
18. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999, 56:33-39. 10.1001/archneur.56.1.33, 9923759.
19. Fahn S, Elton RL. Unified Parkinson's disease rating scale. Recent developments in Parkinson's disease 1987, 153-164. Florham Park, NJ: Macmillan Health Care Information, Fahn S, Marsden CD, Calne D, Goldstein M.
20. Langston JW, Widner H, Goetz CG, Brooks D, Fahn S, Freeman T, Watts R. Core assessment program for intracerebral transplantations (CAPIT). Mov Disord 1992, 7:2-13.
21. Fleisher AS, Chen K, Liu X, Roontiva A, Thiyyagura P, Ayutyanont N, Joshi AD, Clark CM, Mintun MA, Pontecorvo MJ, Doraiswamy PM, Johnson KA, Skovronsky DM, Reiman EM. Using positron emission tomography and florbetapir f 18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to alzheimer disease. Arch Neurol 2011, 68:1404-1411. 10.1001/archneurol.2011.150, 21747008.
22. Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, Adler LP, Kovnat KD, Seibyl JP, Arora A, Saha K, Burns JD, Lowrey MJ, Mintun MA, Skovronsky DM,Florbetapir F 18 Study Investigators Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects. J Nucl Med 2012, 53:378-384. 10.2967/jnumed.111.090340, 22331215, Florbetapir F 18 Study Investigators.
23. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. J Dent Res 1973, 33:613-619.
24. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinsons disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008, 79:1331-1338. 10.1136/jnnp.2007.127878, 18653550.
25. Maetzler W, Liepelt I, Reimold M, Reischl G, Solbach C, Becker C, Schulte C, Leyhe T, Keller S, Melms A, Gasser T, Berg D. Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiol Dis 2009, 34:107-112. 10.1016/j.nbd.2008.12.008, 19162186.
26. Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G, Cowie TF, Dickinson KL, Maruff P, Darby D, Smith C, Woodward M, Merory J, Tochon-Danguy H, O'Keefe G, Klunk WE, Mathis CA, Price JC, Masters CL, Villemagne VL. Imaging beta-amyloid burden in aging and dementia. Neurology 2007, 68:1718-25. 10.1212/01.wnl.0000261919.22630.ea, 17502554.
27. Mintun MA, LaRossa GN, Sheline YI, Dence CS, Lee SY, Mach RH, Klunk WE, Mathis CA, DeKosky ST, Morris JC. 11C]PIB in a nondemented population: Potential antecedent marker of Alzheimer disease. Neurology 2006, 67:446-452. 10.1212/01.wnl.0000228230.26044.a4, 16894106.
28. McKeith I, OBrien JT, Walker Z, Tatsch K, Booij J, Darcourt J, Padovani A, Giubbini R, Bonuccelli U, Volterrani D, Holmes C, Kemp P, Tabet N, Meyer I, Reininger C,DLB Study Group Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 2007, 6:305-313. 10.1016/S1474-4422(07)70057-1, 17362834, DLB Study Group.
29. Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: A meta-analysis of published studies. Parkinsonism Relat Disord 2012, 18:225-229. 10.1016/j.parkreldis.2011.09.015, 21975260.
30. Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain 2011, 134:1647-1657. 10.1093/brain/awr089, 3102241, 21555336.
31. Hohl U, Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J. DIagnostic accuracy of dementia with lewy bodies. Arch Neurol 2000, 57:347-351. 10.1001/archneur.57.3.347, 10714660.
32. Walker Z, Jaros E, Walker RWH, Lee L, Costa DC, Livingston G, Ince PG, Perry R, McKeith I, Katona CL. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 2007, 78:1176-1181. 10.1136/jnnp.2006.110122, 2117602, 17353255.
33. Zaccai J, Brayne C, McKeith I, Matthews F, Ince PG. On behalf of the MRC Cognitive Function ANS. Patterns and stages of alpha-synucleinopathy. Neurology 2008, 70:1042-1048. 10.1212/01.wnl.0000306697.48738.b6, 18362284.
34. Colloby SJ, McParland S, O'Brien JT, Attems J. Neuropathological correlates of dopaminergic imaging in Alzheimer's disease and Lewy body dementias. Brain 2012, 135:2798-2808. 10.1093/brain/aws211, 22961551.
35. Roselli F, Pisciotta NM, Perneczky R, Pennelli M, Aniello MS, De Caro MF, Ferrannini E, Tartaglione B, Defazio G, Rubini G, Livrea P. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: A 123I-FP-CIT SPECT study. Mov Disord 2009, 24:2097-2103. 10.1002/mds.22702, 19705471.
36. O'Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, Aarsland D, McKeith IG. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 2004, 61:919-25. 10.1001/archneur.61.6.919, 15210531.
37. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ. Striatal and extrastriatal dysfunction in Parkinson's diease and dementia: a 6-18 F fluoro-L-dopa PET study. Brain 2002, 125:1358-1368. 10.1093/brain/awf134, 12023324.
38. Ravina B, Marek K, Eberly S, Oakes D, Kurlan R, Ascherio A, Beal F, Beck J, Flagg E, Galpern WR, Harman J, Lang AE, Schwarzschild M, Tanner C, Shoulson I. Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord 2012, 27:1392-1397. 10.1002/mds.25157, 22976926.
39. Gomperts SN, Locascio JJ, Rentz DM, Santarlasci A, Marquie M, Johnson KA, Growdon JH. Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia. Neurology 2013, 80:1-7.
40. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977, 33:159-174. 10.2307/2529310, 843571.